Lung cancer is a major global health concern and ranks as the deadliest type of cancer, accounting for approximately one in five cancer-related deaths
Tagrisso has been reported on by Bloomberg to demonstrate its ability to delay the progression of advanced lung cancer when combined with chemotherapy. This would mark a significant advancement in the treatment of this deadly disease. The study’s findings indicate that the combination of Tagrisso and chemotherapy extended the time before the worsening of advanced non-small cell lung tumors by an impressive nine months compared to Tagrisso alone.
These results are expected to set a new standard for delaying the progression of the disease, according to Susan Galbraith, Executive Vice President of Oncology Research and Development at AstraZeneca. Tagrisso is already the UK-based pharmaceutical company’s best-selling drug, generating $5.4 billion in revenue and contributing significantly to the company’s 2022 earnings.
David Fredrickson, Executive Vice President of Oncology at AstraZeneca, emphasized the importance of advancing treatment options beyond monotherapy, highlighting Tagrisso as the cornerstone of lung cancer treatment for patients with a specific genetic mutation known as EGFR. According to the study, patients receiving the combination therapy experienced a median survival time of 25.5 months and 29.4 months before the cancer progressed. In contrast, those who received Tagrisso alone had median survival times of 16.7 months and 19.9 months, respectively. Although overall survival data is still preliminary, the results favour Tagrisso combined with chemotherapy.
Despite this positive development, analysts from Bloomberg Intelligence, John Murphy and Sam Fazeli, noted that the study’s results present a mixed message and create a competitive landscape for rival pharmaceutical companies like Johnson & Johnson. They highlighted the significant success of AstraZeneca in achieving the primary endpoint of the trial but expressed concern about the absence of a clear trend favouring an overall survival benefit.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Kathy Griffin speaks out on COVID-19 vaccine after lung cancerThe comedian has discussed the precautions she continues to take after having a portion of her lung removed.
Read more »
Donated organs likely caused Legionnaires' disease in 2 lung transplant recipients: CDCA CDC report published Thursday has documented the first time transplanted organs likely led to Legionnaires' after two lung transplant recipients contracted the disease.
Read more »
Flu: Interferon-gamma from T follicular helper cells is required to create lung-resident memory B cellsDuring a bout of influenza, B cells interact with other immune cells and then take different paths to defend the body. One path is the B cells that differentiate into lung-resident memory B cells, or lung-BRMs, that are critical for pulmonary immunity. These long-lived, non-circulating lung-BRMs migrate to the lungs from draining lymph nodes and reside there permanently as the first layer of defense that can quickly react to produce antibodies in a future infection.
Read more »
Texans safety Jalen Pitre “in good spirits,’ day to day as he recovers from bruised lung, not practicing yetTexans safety was hospitalized with bruised lung
Read more »
A Cure for COPD? Transplanting Patients’ Own Lung Cells Shows Great PromiseResearchers have demonstrated the potential to heal injured lung tissue in chronic obstructive pulmonary disease (COPD) patients using their own lung cells for the first time. A study recently presented at the European Respiratory Society International Congress in Milan, Italy reported that 17 pa
Read more »
“Liturgy of Anti-Tank Obstacles” Shows the Transformations of Life in UkraineA documentary short by the Ukrainian filmmaker Dmytro Sukholytkyy-Sobchuk shows sculptors of religious statues using their tools and training for war.
Read more »